Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA study - Trial 2022-003060-25
Access comprehensive clinical trial information for 2022-003060-25 through Pure Global AI's free database. This phase not specified trial is sponsored by Menarini International Operations Luxembourg SA and is currently Ongoing. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2022-003060-25
Ongoing
Trial Details
EU Clinical Trials Register • 2022-003060-25
Open-label, multicenter, multinational, interventional Clinical Trial to assess Efficacy and Safety of the extemporaneous combination of Nebivolol and Ramipril in hypertensive patients - ARTEMISIA study
Study Focus
Sponsor & Location
Menarini International Operations Luxembourg SA
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Any patient who meets any of the following criteria will not qualify for entry into the study:
ICD-10 Classifications
Cardiovascular disease, unspecified
Hypertensive heart disease
Heart disease, unspecified
Atherosclerotic cardiovascular disease, so described
Atherosclerotic heart disease
Data Source
EU Clinical Trials Register
2022-003060-25
Non-Device Trial